Astria Therapeutics Inc. (ATXS)
Astria Therapeutics Statistics
Share Statistics
Astria Therapeutics has 56.43M shares outstanding. The number of shares has increased by 2.79% in one year.
| Shares Outstanding | 56.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 45.38M |
| Failed to Deliver (FTD) Shares | 369 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 2.68M, so 4.76% of the outstanding shares have been sold short.
| Short Interest | 2.68M |
| Short % of Shares Out | 4.76% |
| Short % of Float | 5.56% |
| Short Ratio (days to cover) | 7.79 |
Valuation Ratios
The PE ratio is -3.17 and the forward PE ratio is -6.31.
| PE Ratio | -3.17 |
| Forward PE | -6.31 |
| PS Ratio | 0 |
| Forward PS | 340.6 |
| PB Ratio | 0.95 |
| P/FCF Ratio | -3.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Astria Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.73, with a Debt / Equity ratio of 0.
| Current Ratio | 21.73 |
| Quick Ratio | 21.73 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.14 |
| Cash Flow / Debt | -208.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.3% and return on capital (ROIC) is -34.11%.
| Return on Equity (ROE) | -0.3% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -34.11% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.24M |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -37.63% in the last 52 weeks. The beta is 0.71, so Astria Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | -37.63% |
| 50-Day Moving Average | 9.2 |
| 200-Day Moving Average | 10.24 |
| Relative Strength Index (RSI) | 33.43 |
| Average Volume (20 Days) | 318.07K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -83.03M |
| Net Income | -72.89M |
| EBITDA | -83.03M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.42 |
Balance Sheet
The company has 175.53M in cash and 329.00K in debt, giving a net cash position of 175.20M.
| Cash & Cash Equivalents | 175.53M |
| Total Debt | 329.00K |
| Net Cash | 175.20M |
| Retained Earnings | -580.53M |
| Total Assets | 361.64M |
| Working Capital | 336.14M |
Cash Flow
In the last 12 months, operating cash flow was -68.44M and capital expenditures -25.00K, giving a free cash flow of -68.47M.
| Operating Cash Flow | -68.44M |
| Capital Expenditures | -25.00K |
| Free Cash Flow | -68.47M |
| FCF Per Share | -2.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ATXS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -32.1% |
| FCF Yield | -16.08% |
Analyst Forecast
The average price target for ATXS is $27, which is 258.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $27 |
| Price Target Difference | 258.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Aug 20, 2021. It was a backward split with a ratio of 1:6.
| Last Split Date | Aug 20, 2021 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 10.24 |
| Piotroski F-Score | 2 |